Here are highlights from Monday's Analyst Blog:

PartnerRe Adjusted, Still a Buy

PartnerRe Ltd's (NYSE: PRE) 3Q08 operating income of $121.3 million or $2.27 per diluted share was ahead of estimates. While the core results were strong, the company suffered substantial losses in the investment portfolio and large hurricane losses.

Based on 3Q08 results, we are moderating our FY08 and FY09 estimates to $10.39 per share and $9.55 per share respectively. At the current price, the shares of PRE trade at 0.85x its 3Q08 book value of $65.38 per share, almost at the bottom of its 10-year range, substantially below the peak of 1.73x and at a 11.8% premium to the peer group median.

Zimmer Valuation Lowered

Zimmer Holdings (NYSE: ZMH) is a global leader in the design, development, manufacture, and marketing of reconstructive implants, and trauma and related orthopedic surgical products.

We believe the increase in unemployment will reduce the number of insured patients. As a result, procedures may be subject to delays, reducing revenue growth in the near-term. On the upcoming call, we are listening for whether the stronger dollar will reverse the tailwind revenues have received over the past few years, if efforts to increase financial leverage during the recent credit crisis may have met obstacles, and if efforts to control prices of commodity inputs (futures) may pressure gross margins as prices have since retreated.

Corporate Executive Board a Sell

We maintain our Sell rating on shares of The Corporate Executive Board (NASDAQ: EXBD) following the release of third-quarter results.

We believe the shares of The Corporate Executive Board are overvalued near current levels, in light of the weak conditions in the current operating environment. Although Q3 results came in ahead of expectations, we have reduced our fourth-quarter 2008 and full-year 2009 EPS estimates as the company's outlook remains modest, in part due to the fact that EXBD has yet to improve its cross-sell ratio.

Heinz Looking to Play Catch-Up

Growth in the domestic businesses, strengthening international operations and the reallocation of resources in favor of key brands are the major positive trends for the H. J. Heinz Company (NYSE: HNZ). However, the gross margin is declining due to higher commodity costs. Despite cost pressure, strong pricing of 3.5% to 4.5% has allowed the company to report positive earnings surprises in the last nine quarters.

Management expects net sales to increase in the 6% range in fiscal 2009, driven by new product introductions and positive pricing. However, since the stock is only in the middle of its historical valuation range, the Hold recommendation is maintained.

Starwood Hotels No Longer So Hot

We continue to believe that Starwood Hotels & Resorts Worldwide Inc.'s (NYSE: HOT) well-positioned portfolio will benefit given an increase in demand. However, we currently do not expect an improvement in the operating environment in the near term, and we expect that challenges will persist through 2009. Therefore, we have downgraded our rating on shares from Buy to Hold. Our price target of $20 reflects an enterprise value/EBITDA multiple of 7.0x our 2009 EBITDA estimate.

While the slowing economy has been evident for some time, we had previously expected Starwood to outperform its peers in part due to its concentration in high-end properties, its international exposure, and its relatively limited timeshare business. Although third-quarter results exceeded our expectation, a portion of the upside was due to timing. Also, management's outlook regarding the fourth quarter and 2009 make clear the fact that the economic factors will hurt Starwood more than we had originally anticipated.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

SOURCE: Zacks.com

Zacks.com 
Mark Vickery 
Web Content Editor 
312-265-9380 
Visit: www.zacks.com

"We have appreciated the engagement of the Abbott Spine management team as we have been able to move ahead briskly with our integration planning. We are excited to now work together to execute those plans and begin to take advantage of the great potential and strategic opportunity represented by this combination."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

The acquisition is expected to close in the fourth quarter of 2008. The boards of directors of both companies have approved the transaction, which is subject to regulatory approvals and other customary closing conditions.

David Dvorak, president and CEO of Zimmer, said: "This acquisition is another significant step in executing our strategies to position Zimmer for sustained growth in the future. We are excited to be adding a number of innovative products that round out the Zimmer Spine portfolio and help us build toward critical mass in this important business segment."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related orthopaedic surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer's 2007 sales were approximately $3.9 billion. The Company is supported by the efforts of approximately 8,500 employees worldwide.

For more information about Zimmer, visit www.zimmer.com

SOURCE Zimmer Holdings, Inc.

http://www.zimmer.com